BOGANI, COSTANZA

BOGANI, COSTANZA  

Medicina Sperimentale e Clinica  

Mostra records
Risultati 1 - 20 di 25 (tempo di esecuzione: 0.034 secondi).
Titolo Data di pubblicazione Autore(i) File
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 2007 Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi
Breast cancer resistance protein (BCRP) expression and activity in mitochondria of different multiple drug-resistant (MDR) cancer cell lines 2009 Mazzanti, R; Solazzo, M; Fantappie, O; D'Amico, M; Sassoli, C; Tani, A; Cipriani, G; Bogani, C; Pestrin, M; Formigli, L
Caratterizzazione di alterazioni molecolari relative alla patogenesi delle Neoplasie Mieloproliferative Croniche 2009 C. Bogani
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 2005 Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM.
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 2013 Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 2009 Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T.
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 2015 Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 2008 Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; Cristophe Desterke; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi.
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 2006 Vannucchi, A.; Guglielmelli, P.; Antonioli, E.; Mappa, S.; Pancrazzi, A.; Bogani, C.; Ponziani, V.; Bosi, A.
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 2009 Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A.
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 2015 Salati, Simona; Zini, Roberta; Nuzzo, Simona; Guglielmelli, Paola; Pennucci, Valentina; Prudente, Zelia; Ruberti, Samantha; Rontauroli, Sebastiano; Norfo, Ruggiero; Bianchi, Elisa; Bogani, Costanza; Rotunno, Giada; Fanelli, Tiziana; Mannarelli, Carmela; Rosti, Vittorio; Salmoiraghi, Silvia; Pietra, Daniela; Ferrari, Sergio; Barosi, Giovanni; Rambaldi, Alessandro; Cazzola, Mario; Bicciato, Silvio; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella
JAK PI3K/mTOR COMBINATION THERAPY 2013 Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 2007 Paola Guglielmelli; Lorenzo Tozzi; Alessandro Pancrazzi; Costanza Bogani; Elisabetta Antonioli; Vanessa Ponziani; Giada Poli; Roberta Zini; Sergio Ferrari; Rossella Manfredini; Alberto Bosi; Alessandro M Vannucchi.
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. 2014 Norfo R;Zini R;Pennucci V;Bianchi E;Salati S;Guglielmelli P;Bogani C;Fanelli T;Mannarelli C;Rosti V;Pietra D;Salmoiraghi S;Bisognin A;Ruberti S;Rontauroli S;Sacchi G;Prudente Z;Barosi G;Cazzola M;Rambaldi A;Bortoluzzi S;Ferrari S;Tagliafico E;Vannucchi AM;Manfredini R
Mitochondrial expression and functional activity of Breast Cancer Resistance Protein in different multiple drug-resistant cell lines 2009 M. Solazzo; O. FANTAPPIE'; M. D'Amico; C. Sassoli; A. Tani; G. Cipriani; C. Bogani; L. Formigli; R. Mazzanti
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 2007 Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 2013 Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM.
mTOR/JAK INHIBITOR COMBINATION THERAPY 2012 A.M. VANNUCCHI; C. BOGANI; P. GUGLIELMELLI; NOVARTIS PHARMA AG; INCYTE CORP.
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 2011 Guglielmelli, P.; Tozzi, L.; Bogani, C.; Iacobucci, I.; Ponziani, V.; Martinelli, G.; Bosi, A.; Vannucchi, A.M. .
Preclinical models for drug selection in myeloproliferative neoplasms. 2013 Bartalucci N;Bogani C;Vannucchi AM